jnj-64264681
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2018 (NCT03607513)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cytochrome P450 2C9INHIBITOR
CYP2C9 inhibitor
- Cytochrome P450 3A5INHIBITOR
CYP3A5 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N[C@H]1CCC[C@H]1NC(=O)c1sc2nccc3c2c1NC(=O)N3c1cnc(CC(C)C)cc1C- Mol. weight
- 518.64 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314920 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06788509 | Phase 1 | Dec 30, 2024 | Johnson and Johnson |
| NCT04657224 | Phase 1 | Dec 28, 2020 | Janssen Pharmaceutica NV |
| NCT04210219 | Phase 1 | Jan 15, 2020 | Janssen Pharmaceutica NV |
| NCT03607513 | Phase 1 | Jul 31, 2018 | Johnson and Johnson |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 1 | 2020 |
| Johnson and Johnson | For profit | 2 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1